Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants
- Conditions
- Lung Cancer
- Registration Number
- NCT00899028
- Lead Sponsor
- Vanderbilt University Medical Center
- Brief Summary
RATIONALE: Studying samples of tissue, blood, sputum, and urine from patients with lung cancer and from healthy participants in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is looking at biomarkers for lung cancer using tissue samples from patients with lung cancer and from healthy participants.
- Detailed Description
OBJECTIVES:
* To identify new molecular abnormalities specific to the development of squamous cell carcinoma of the lung.
* To determine the prevalence of candidate biomarkers in lung cancer progression.
* To determine the odds of developing lung cancer according to biomarker status in preinvasive lesions.
* To determine the odds of developing lung cancer according to proteomic biomarker status in the normal bronchial epithelium of high-risk patients.
OUTLINE: This is a multicenter study.
Tissue samples are collected at the time of fluorescence bronchoscopy for laboratory biomarker studies. Blood, sputum, and urine samples are also collected. Gene and protein expression studies are performed on the samples using comparative genomic hybridization array, 3q oligonucleotide microarray, matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF), fluorescence in situ hybridization (FISH), and immunohistochemistry (IHC).
Patients' medical records are reviewed to collect information about the patient's past medical history and pertinent laboratory and radiography results.
Patients and healthy volunteers are followed annually via telephone or a mailed questionnaire.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 689
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of new molecular markers specific to the development of squamous cell lung cancer Prevalence of candidate biomarkers in lung cancer progression Odds of developing lung cancer according to biomarker status
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (4)
Vanderbilt-Ingram Cancer Center - Cool Springs
🇺🇸Nashville, Tennessee, United States
Vanderbilt-Ingram Cancer Center at Franklin
🇺🇸Nashville, Tennessee, United States
Veterans Affairs Medical Center - Nashville
🇺🇸Nashville, Tennessee, United States
Vanderbilt-Ingram Cancer Center
🇺🇸Nashville, Tennessee, United States